Prostate cancer kills 10,000 British men annually. Although regarded as one of the less dangerous forms of the disease, it is difficult to diagnose and is often discovered too late for surgery. Treatment, therefore, often becomes more about control than cure. Enter Casodex from AstraZeneca, an antiandrogen drug which works by lowering levels of testosterone in the bloodstream and slowing or stopping the growth of the tumour. Approved in June for use by itself as an 'early-stage' treatment, it is no more effective than existing treatments but beats them hands down in the quality-of-life stakes. It reduces common side effects, including impotence and genital shrivelling. Well received by doctors, Casodex looks set to become one of AstraZeneca's biggest earners.
From software developers to security engineers, these are the women powering up the ranks of the UK tech sector.
The sausage-maker on building a £25m brand in five years, why he'll never sell the family business, and Heck's cheeky sausage for the Royal Wedding.
Leadership development experts Jay Conger and Allan Church reveal the secret ingredients of high-potential talent.
Success does not have to be zero sum - it can be win-win for all - but how can you cultivate a new ecosystem for maximum impact?
The e-commerce giant launches checkout-free bricks and mortar store.
Over half a million people in the UK suffer from work-related stress and depression. Are you one of them?